Apology for Exclusion: Public Health Tobacco Control Act 2023

Regulations by 2FIRSTS.ai
Dec.25.2023
Apology for Exclusion: Public Health Tobacco Control Act 2023
Malaysia's Health Minister, Datuk Seri Dr Adham Baba, apologizes for not including the "Gen Excluded from Smoking" policy in the Public Health Tobacco Control Act 2023.

According to a report by the Malaysian media outlet Borneo Post on January 24th, the Minister of Health, Datuk Seri Dr Adham Baba, admitted that he does not have the authority to implement a nationwide smoking ban as he is not the Minister of Religion. However, he emphasized his responsibility as the Minister of Health to ensure that smokers and their actions do not harm non-smokers, as smoking is detrimental to health.

 

Zulfikar also serves as the Chief Strategist of the Integrity Party. At the Integrity Party's 2023 National Congress, he responded to representatives' proposal, the "2023 Public Health Tobacco Control Bill." He once again apologized to party delegates for not including the "Generation Excluded from Smoking" (GEG) policy in the legislation, which aimed at achieving a smoke-free generation.

 

On the 30th of last month, the "2023 Public Health Tobacco Product Control Bill" was passed in the lower house of Parliament through a voice vote. However, it is worth noting that this bill has removed the previously set GEG policy, which prohibited the smoking and possession of tobacco products for individuals born after 2007. The policy has now been replaced with a ban on individuals under the age of 18 purchasing tobacco products, tobacco alternatives, and smoking devices.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
HB337 Moves Forward: Cigarette and Nicotine Taxes Set to Rise in Utah
HB337 Moves Forward: Cigarette and Nicotine Taxes Set to Rise in Utah
Utah lawmakers are advancing HB337, a bill that would raise the state cigarette tax by $2 per pack and restructure taxes on other nicotine products. The proposal replaces weight-based taxes with percentage-based rates and removes reduced rates for certain modified risk products. Supporters say it will curb youth tobacco use, while opponents warn of cross-border shopping and harm to consumers seeking alternatives.
Feb.17
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
Kansas Senate approves tougher vape rules to target unlicensed products and child-directed ads
The Kansas Senate approved Senate Bill 355 on Wednesday, aiming to crack down on unlicensed vaping products and eliminate advertisements geared toward children. The bill, backed by major tobacco companies, would impose the same licensing and advertising requirements on e-cigarettes as other nicotine products and require every e-cigarette manufacturer doing business in Kansas to obtain a license, with a $2,500 application fee.
Feb.13 by 2FIRSTS.ai
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
Ohio Supreme Court takes up appeal that could define state limits on illegal vape sales enforcement
The Ohio Supreme Court has agreed to hear Attorney General Dave Yost’s appeal seeking to revive lawsuits against three Ohio vape retailers. Lower courts dismissed the cases, finding that federal law governs whether vaping products may be marketed and sold.
Mar.06 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24